From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy

SIMPLE SUMMARY: Immune control inhibitor drugs (anti-PD1/PD-L1/CTLA-4) (ICIs) are showing efficacy in the treatment of lung cancer. Currently the only biomarker with clinical utility for ICIs, such as the expression of PDL1, does not appear to be perfect or effective. Our working group is conducting...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers (Basel)
Hauptverfasser: Sesma, Andrea, Pardo, Julián, Cruellas, Mara, Gálvez, Eva M., Gascón, Marta, Isla, Dolores, Martínez-Lostao, Luis, Ocáriz, Maitane, Paño, José Ramón, Quílez, Elisa, Ramírez, Ariel, Torres-Ramón, Irene, Yubero, Alfonso, Zapata, María, Lastra, Rodrigo
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2020
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7602200/
https://ncbi.nlm.nih.gov/pubmed/33066479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102974
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge